What is OS Therapies's gross proceeds?

OS Therapies (OSTX) reported gross proceeds of $625K in Q4 2025.

What does gross proceeds mean?

This metric represents the total cash inflows received from financing activities, such as equity offerings or debt issuances, before the deduction of any associated issuance costs or fees. It serves as a primary indicator of the company's ability to raise external capital to fund clinical development and operational runway. Tracking this provides insight into the company's liquidity position and its success in securing funding from capital markets.

OS Therapies OSTX Gross Proceeds

Gross Proceeds at other companies

Spectral AI, Inc.MDAI

$7.6M+300%

Alpha CognitionACOG

$5.25M—

Spectral AI, Inc.MDAI

$7.6M+300%

XTI Aerospace, Inc.XTIA

$22.8M—

KEE

Keel Infrastructure Corp. Common StockKEEL

$142.27M—

Bit DigitalBTBT

$147.4M—

Other financials

Income statement

See full

Operating income-$10.2M-103%

Net income-$10.4M-168%

EPS (diluted)-$0.27-50.0%

Balance sheet

See full

Cash & equivalents$917.6K-69.1%

Total debt$20.0M—

Total equity-$10.8M-159%

Total assets$7.3M+71.7%

Cash flow

See full

Operating cash flow-$4.6M-32.6%

CapEx$316.4K—

Free cash flow-$3.7M—

Valuation

See full

Market cap$84.62M+66.4%

Enterprise value$103.7M—

Returns & leverage

See full

Return on equity470%—

Debt / equity-1.8×—

Current ratio0.1×-1.1×

Where this comes from

Reported directly by OS Therapies in its filing.

Tagged under the XBRL concept osti:GrossProceeds.

The official record: OS Therapies’s 10-K, filed March 31, 2026, on SEC EDGAR. View the filing →

Ask your AI about OS Therapies's gross proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is OS Therapies's gross proceeds?: OS Therapies (OSTX) reported gross proceeds of $625K in Q4 2025.
What does gross proceeds mean?: This metric represents the total cash inflows received from financing activities, such as equity offerings or debt issuances, before the deduction of any associated issuance costs or fees. It serves as a primary indicator of the company's ability to raise external capital to fund clinical development and operational runway. Tracking this provides insight into the company's liquidity position and its success in securing funding from capital markets.